Gmsbags Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 15-12-2024
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.28 Cr
as on 15-12-2024
- Revenue 109.98%
(FY 2022)
- Profit -319.00%
(FY 2022)
- Ebitda 298.39%
(FY 2022)
- Net Worth -1682.84%
(FY 2022)
- Total Assets 112.87%
(FY 2022)
About Gmsbags Biotech
The Company is engaged in the Home & Lifestyle Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹1.28 Cr.
Shruthi Mallikarjuna, Manjunath Gorantla, and Gorantla Devi serve as directors at the Company.
- CIN/LLPIN
U19115KA2019PTC128382
- Company No.
128382
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Davangere, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Gmsbags Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manjunath Gorantla  | Managing Director | 30-Sep-2019 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shruthi Mallikarjuna | Director | 30-Sep-2019 | Current |
| Gorantla Devi | Director | 30-Sep-2019 | Current |
Financial Performance of Gmsbags Biotech.
Gmsbags Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 109.98% increase. The company also saw a substantial fall in profitability, with a 319% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1682.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gmsbags Biotech?
In 2022, Gmsbags Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 Jun 2021 | ₹1.28 Cr | Open |
How Many Employees Work at Gmsbags Biotech?
Gmsbags Biotech has a workforce of 12 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gmsbags Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gmsbags Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
